Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Trial Profile

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Z-Butylidenephthalide (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Everfront Biotech
  • Most Recent Events

    • 27 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Dec 2021.
    • 27 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Dec 2020.
    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top